KROSKeros Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Keros Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KROSThis | $219M#8 | — | 0.8x#1 | 0.9x#3 | 6775.0%#1 | 146.4%#4 | 27.7%#1 | 33.2%#1 | — | — | — | — |
| CAMP | $242M#2 | — | — | 69.2x#8 | 436.5%#2 | -55.2%#13 | -1502.4%#7 | — | — | — | — | — |
| RNAC | $242M#3 | — | — | 605.1x#10 | -99.0%#9 | -68.3%#15 | -35851.3%#10 | — | — | — | — | — |
| WHWK | $237M#4 | — | 1.3x#6 | 33.1x#7 | -72.5%#8 | 67.7%#5 | -1601.1%#8 | -11.3%#6 | — | — | 111.7%#2 | — |
| NATR | $232M#5 | 13.2x#2 | 1.7x#10 | 0.5x#2 | 5.7%#6 | 153.7%#3 | 5.2%#4 | 14.3%#3 | — | 9#1 | -19.8%#4 | — |
| ZNTL | $226M#6 | — | 1.6x#8 | — | -100.0%#10 | 17.4%#7 | — | -95.4%#11 | — | — | — | — |
| SIGA | $221M#7 | — | 1.3x#7 | 2.3x#4 | -31.8%#7 | -60.7%#14 | 25.1%#2 | 14.1%#4 | — | — | -57.6%#6 | 19.5%#1 |
| ELDN | $218M#9 | — | 6.6x#13 | — | — | -26.1%#11 | — | -138.2%#13 | — | — | — | — |
| BRVE | $2.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| NKTX | $209M#10 | — | 0.8x#2 | — | — | 4.3%#9 | — | -42.0%#7 | — | — | 51.8%#3 | — |
| KRRO | $208M#11 | — | 2.0x#11 | 32.5x#6 | 181.5%#3 | -40.3%#12 | -1906.4%#9 | -113.6%#12 | -155.2%#3 | — | -54.3%#5 | — |
| TNXP | $200M#13 | — | 0.9x#3 | 15.3x#5 | 29.8%#4 | 4.6%#8 | -959.1%#6 | -55.8%#9 | -234.8%#4 | — | — | — |
| ANTX | $198M#14 | — | 2.6x#12 | — | — | 31.5%#6 | — | -46.3%#8 | — | — | 306.2%#1 | — |
| PEPG | $202M#12 | — | 1.7x#9 | — | — | 0.4%#10 | — | -75.0%#10 | — | — | — | — |
| ORMP | $194M#15 | 1.1x#1 | 1.0x#4 | 97.1x#9 | — | 573.1%#2 | -754.4%#5 | 0.0%#5 | -4.4%#2 | — | — | — |
| ORGO | $178M#16 | — | 1.2x#5 | 0.3x#1 | 17.0%#5 | 4011.1%#1 | 7.9%#3 | 25.0%#2 | 23.2%#1 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice